STOCK TITAN
  1. Home
  2. News
  3. FUSN

Fusion Pharmaceuticals Inc - FUSN STOCK NEWS

Welcome to our dedicated news page for Fusion Pharmaceuticals (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fusion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fusion Pharmaceuticals's position in the market.

News
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Rhea-AI Summary
Fusion Pharmaceuticals Inc. announces a special meeting of shareholders to approve an arrangement with AstraZeneca plc, where AstraZeneca will acquire all outstanding shares for US$21.00 per share in cash plus a contingent value right of US$3.00 per share. The meeting is set for May 29, 2024, with a record date of April 16, 2024, and will be held virtually. The board of directors unanimously recommends shareholders vote FOR the arrangement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Rhea-AI Summary
Fusion Pharmaceuticals Inc. presents promising interim data on FPI-2265 for metastatic castration-resistant prostate cancer at AACR 2024. Results show efficacy in heavily pretreated patients, with a PSA50 response rate of 50%. The drug demonstrates improvement in secondary endpoints and is generally well-tolerated. Fusion plans to initiate Phase 2/3 trials in 2024 for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
clinical trial
-
News
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Rhea-AI Summary
Fusion Pharmaceuticals Inc. announced a definitive agreement to be acquired by AstraZeneca, with a focus on their FPI-2265 Phase 2/3 program for metastatic castration-resistant prostate cancer. The company reported financial results, including a $2 billion transaction value, and provided updates on clinical programs and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
earnings
News
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) to be acquired by AstraZeneca in a $2.4 billion transaction. Fusion's radioconjugate targeting PSMA for prostate cancer and R&D capabilities key in the acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
99.06%
Tags
acquisition
-
News
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fusion Pharmaceuticals Inc. announced the grant of stock option awards to four employees outside the 2020 Stock Option and Incentive Plan. The options allow the purchase of 245,300 shares at an exercise price of $10.79 per share, with a ten-year term and vesting over four years. This move aims to incentivize employee retention and align interests with shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announces the selection of interim efficacy and safety data from the Phase 2 TATCIST clinical trial for a poster presentation at the AACR Annual Meeting 2024, focusing on FPI-2265 in patients with mCRPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
conferences clinical trial
News
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (FUSN) will participate in two investor conferences to discuss their innovative radiopharmaceuticals. The Company will be presenting at the TD Cowen 44th Annual Health Care Conference and Leerink Partners 2024 Global Biopharma Conference, showcasing their advancements in precision medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences
-
News
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) has secured an exclusive worldwide license agreement with Heidelberg University and Euratom for the development of FPI-2265, a cutting-edge PSMA targeted alpha therapy for prostate cancer. The agreement also resolves a patent dispute, setting the stage for significant advancements in radiopharmaceutical treatments. Fusion is set to achieve key milestones in 2024, including data from the TATCIST study and the initiation of a Phase 2/3 registrational study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
-
News
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The presentation will be available via webcast and will feature CEO John Valliant, Ph.D. The event aims to showcase Fusion's advancements in developing next-generation radiopharmaceuticals as precision medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
conferences
News
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the grant of stock options to nine employees outside the 2020 Stock Option and Incentive Plan. The options have an exercise price of $10.59 per share, with a ten-year term and vesting over four years. This was granted as an inducement material to the employees becoming part of the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none
Stock FUSN logo
Fusion Pharmaceuticals Inc

Nasdaq:FUSN

FUSN Rankings

#1945 Ranked by Market Cap
#282 Ranked by Stock Gains
N/A Ranked by Dividends

FUSN Stock Data

1.81B
63.30M
4.41%
79.16%
6.14%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Canada
Hamilton

About FUSN

fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.